Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

XGEVA (Denosumab) for Lung Cancer: Survival Benefit Suggested by Retrospective Subset Analysis of Key Trial
Author
Howard (Jack) West, MD

Late last year, I reviewed the approval of the agent XGEVA (denosumab) for patients with skeletal metastases from solid tumors after a randomized phase III trial demonstrated a significant reduction in the rate of development of skeletal-related events compared with the pre-existing standard of Zometa (zoledronic acid) for bone metastases. Importantly, there was no difference in overall survival in the trial as a whole, which included patients with multiple myeloma or solid tumors other than breast cancer and prostate cancer (which were each studied in separate trials). A few months later, the publication of the phase III trial came out, and I actually wrote the accompanying editorial, in which I argued that while the results showing improvement in the endpoint of skeletal-related events, no improvement in survival, marginally better side effect profile, but considerably higher cost made XGEVA a very compelling option but not necessarily an iron-clad unchallanged standard of care when the cost vs. benefit of the agent over Zometa is taken into consideration.

Though I suggested that the results were provocative but not overwhelming from the bird's eye view, I raised the point that if overall survival (OS) were to be improved in a subset of patients, the argument favoring XGEVA would be more compelling, as was noted in a very limited way for patients with NSCLC in the randomized trial:

It is therefore notable that, in a post hoc analysis of OS in the Henry et al11 trial, the HR for NSCLC was statistically superior with denosumab for patients with advanced NSCLC.

Among the many interesting presentations from the World Conference on Lung Cancer in Amsterdam was one by Dr. Giorgio Scagliotti that provides far more detail on the post hoc (retrospective) analysis of patients with lung cancer from this trial. Dr. Weiss provided a summary of the presentation in his great review of that day, but here I'll provide a little more information (primarily just the "picture's worth a thousand words" synopsis).

The overall trial enrolled 1776 patients with a range of cancer types, of which 40% had NSCLC and 9% had SCLC: this large subset of 811 patients with lung cancer served as the basis for this presentation. Looking at the entire group with lung cancer, there was a statistically significant 20% improvement in OS that translated to a 1.2 month prolongation in median OS, as illustrated in the figure below:

os-denosumab-vs-zoledronic-acid

(click on image to enlarge)

In fact, this benefit appeared to be of the same magnitude in patients with NSCLC or SCLC, as shown below:

os-nsclc-denos-vs-zoled os-sclc
Finally, as noted by Dr. Weiss, within the group of patients with NSCLC (702 of the 811 with lung cancer), the benefit seemed comparable in patients with adenocarcinoma vs. squamous cell NSCLC, with a bit higher magnitude of a survival benefit in patients with squamous NSCLC:

os-nsclc-by-histologic-type

As Dr. Weiss suggested in his preliminary discussion of this report, the difference in median survival (in the 1-2 month range for these subsets) appears to underestimate the true benefit, since the curves become more separated out over time.

So what should we make of these data? This was a post hoc subset analysis, which means that the results can't be taken as the gospel: the trial wasn't really designed to answer this question, and you could characterize the positive results as just a "fishing expedition" that happened to show these results that were then highlighted. On the other hand, this is a very large group of patients, and my interpretation is that the survival benefit is likely real even if not 100% proven in a prospective trial, and that it appears to be present for both NSCLC and SCLC, and in both of the main NSCLC subtypes. As Dr. Weiss noted, the mechanism for this apparent survival benefit isn't clear, but there are studies looking into this question in earnest now.

Along with the improvement in SREs and this reported improvement of survival in patients with lung cancer, XGEVA has a similar and really not worse tolerability, a more convenient means of administration (under the skin rather than an IV infusion), and it doesn't require frequent monitoring of kidney function the way Zometa does.

Taken together, my overall take is that there was already a strong if not definitive case to be made for using XGEVA over Zometa in patients with bone metastases from solid tumors, including lung cancer, but cost and question of value were relevant disadvantages that could fairly fit into the equation. However, if we believe that the survival benefit is real and clinically significant (and I do, on both counts, despite the formal caveats of a retrospective analysis of patient subsets), this is enough to convince me that XGEVA is a clearly stronger alternative. In fact, as a therapeutic agent beyond its role as a supportive care agent, XGEVA could frankly be considered a relative bargain in providing a survival benefit of up to a couple of months for a small fraction of the cost of many other agents that we use in this setting (Hello, Avastin!). Though I had expressed some caution about XGEVA in my editorial based on the available data from that analysis, I'm now convinced that the value proposition of it just went way up for the lung cancer community.

Thoughts?

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...

Hi Bluebird,  Welcome to GRACE.  I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had. 

 

A CT would be...

Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on